New antibody drug shows promise for Hard-to-Treat blood cancer

NCT ID NCT06381141

Ongoing Disease control Sponsor: Cullinan Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This early-stage study tests a new drug called CLN-619 in 30 adults with multiple myeloma that has returned or not responded to other treatments. The drug is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug can shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Levine Cancer Institute

Winston-Salem, North Carolina, 27157, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering (MSK)

New York, New York, 10065, United States
Mt. Sinai

New York, New York, 10029, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA